Meeting
2014 ASCO Annual Meeting
The yield of staging investigations in triple-negative breast cancer patients.
Authors
Renee Elizabeth Lester
Tom Baker Cancer Centre, Calgary, AB, Canada
Renee Elizabeth Lester , Kara E. Laing
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 1127)
DOI
10.1200/jco.2014.32.15_suppl.1127
Abstract #
1127
Poster Bd #
220
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Androgen receptor and estrogen receptor imaging in patients with metastatic breast cancer.
First Author: Clasina Marieke Venema
Poster
2014 Breast Cancer Symposium
Vitamin D levels, triple-negative histology, and geography in breast cancer: A retrospective analysis of a large database of oncology practices in the United States.
First Author: Joyce Georges Habib
Poster
2011 ASCO Annual Meeting
ANZ1001 SORBET: Study of Oestrogen Receptor Beta and Efficacy of Tamoxifen—A single-arm, phase II study of the efficacy of tamoxifen in triple-negative but oestrogen receptor beta-positive metastatic breast cancer.
First Author: B. E. Kiely
Poster
2020 ASCO Virtual Scientific Program
Circulating tumor DNA (ctDNA) to evaluate stage III and stage IV metastatic breast cancer (MBC), describe tumor heterogeneity, and outcome.
First Author: Qiang Zhang